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Introduction. Healthcare associated infections (HAIs) and mis-
use of antimicrobials (AMs) represent a growing public health 
problem. The Point Prevalence Surveys (PPSs) find available 
information to be used for specific targeted interventions and 
evaluate their effects. The objective of this study was to estimate 
the prevalence of HAIs and AM use, to describe types of infec-
tions, causative pathogens and to compare data collected through 
three PPSs in Ferrara University Hospital (FUH), repeated in 3 
different years (2011-2013). The population-based sample con-
sists of all patients admitted to every acute care and rehabilitation 
Department in a single day. 
Methods. ECDC Protocol and Form for PPS of HAI and AM use, 
Version 4.2, July 2011. Risk factor analysis was performed using 
logistic regression. 
Results. 1,239 patients were observed. Overall, HAI prevalence 
was 9.6%; prevalence was higher in Intensive Care Units; uri-
nary tract infections were the most common HAIs in all 3 surveys; 
E.coli was the most common pathogen; AM use prevalence was 
51.1%; AMs most frequently administered were fluoroquinolones, 
combinations of penicillins and third-generation cephalosporins. 
According to the regression model, urinary catheter (OR: 2.5) and 
invasive respiratory device (OR: 2.3) are significantly associated 
risk factors for HAIs (p < 0.05).
Conclusions. PPSs are a sensitive and effective method of anal-
ysis. Yearly repetition is a useful way to maintain focus on the 
topic of HAIs and AM use, highlighting how changes in practices 
impact on the outcome of care and providing useful information 
to implement intervention programs targeted on specific issues.
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Summary
Introduction
Healthcare associated infections (HAIs) represent a 
growing public health problem in terms of patient safety 
and economic burden [1-3]. The Center for Disease Con-
trol (CDC) estimates the increased mean length of hos-
pital stay for each HAI to be 7 extra days, ranging from 
1-4 days for urinary tract infections (UTIs) to 7-30 days 
for pneumonia (PN). In Europe, HAIs cause 16 million 
additional days of hospitalization per year, 37,000 re-
lated deaths and 7 billion euros of additional costs (di-
rect costs only) [4]. The Italian National Health Institute 
estimates 450,000-700,000 HAIs per year in Italian hos-
pitals, 30% of which could be prevented; HAIs could 
be directly responsible for 1,350-2,100 avoidable deaths 
per year [5]. Misuse of antimicrobials (AMs) is a grow-
ing public health problem worldwide, associated with an 
increase in drug resistant microorganisms and adverse 
drug reactions that generate huge economic costs [6, 7]. 
The implementation of surveillance systems for both 
HAI and AM use is a relevant topic in modern public 
health  [8, 9]. Although continuous surveillance still 
represents the gold standard for infection control, it re-
quires a huge amount of human and economic resources 
but has rarely been used in multicenter studies. Instead, 
Point Prevalence Surveys (PPS), despite their inherent 
limitations in terms of accuracy of results and possibility 
of bias, are a highly feasible alternative, easier to per-
form even on large scale multicenter studies, less expen-
sive and less time consuming. PPSs offer many benefits, 
including easy repeatability and the ability to provide 
meaningful information to be used for specific targeted 
interventions. The introduction of standardized proto-
cols such as the European Center for Disease Control 
(ECDC) Protocol for PPS of HAI and AM use in acute 
care hospitals, version 4.2 2011-2012  [10], guarantees 
consistency of results and easy repeatability. Results of 
local surveys may also be used for yearly intra-hospital 
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comparison or benchmarking at regional, national or in-
ternational level. In Ferrara University Hospital (FUH), 
infection and AM stewardship by PPS began in 1992, 
with a local Protocol and data entry form, updated over 
the years in agreement with the literature references [11]. 
This Protocol was used until 2011, when FUH partici-
pated in the first full scale ECDC PPS, October 2011.
The survey was repeated in 2012 and 2013. Objectives 
of these studies were: to estimate the overall burden of 
HAIs and use of AMs in the FUH; to describe HAIs and 
AM use by type of functionally homogeneous wards; to 
allow a comparison of data collected during three sur-
veys and with Italian and European data.
Methods 
The surveys took place in October 2011, November 2012 
and November 2013 in the FUH, a tertiary care hospi-
tal with 857 beds in 2011 and, after moving to a new 
hospital in 2012, with 711 beds. The materials and tools 
developed for the ECDC PPS of HAI and AM use in 
acute care hospitals were used for these surveys: the PPS 
protocol and codebook v4.2, including the case defini-
tions of HAI, PPS data entry forms in an editable format 
for translation purposes, PPS hospital software HELIC-
SWin.net, User manual – PPS hospital software HELIC-
SWin.net [10]. All acute wards were included, except for 
Day-surgery and Day-Hospital departments. The study 
included all patients admitted to the ward before or at 8 
a.m. and not discharged from the ward at the time of the 
survey, including neonates, if born before/at 8 a.m. For 
each ward, data had to be collected in a single day. Data 
collection for each survey was completed in two weeks. 
The surveys were carried out by trained medical doctors 
of the Postgraduate School of Hygiene and Preventive 
Medicine of Ferrara University, supported by doctors 
and nurses of the Hospital Network for Infection Control 
of each ward. The ECDC standard “Patient data form” 
was used, structured according to the following sections: 
demographic data, admission data, clinical data, AM use 
and HAI data [10]. 
Demographic, admission and clinical data, useful for 
identifying patient-based denominator data and risk fac-
tors, included: ward name, survey date, patient counter, 
age, sex, date of admission, surgery since admission, 
McCabe score [12], invasive devices in place on survey 
date (central vascular catheter-CVC, peripheral vascu-
lar catheter-PVC, urinary catheter, intubation). Only 
any active HAI on the survey date was recorded on the 
form [10]. 
Data collected for HAI included: presence of a relevant 
invasive device before onset (intubation for PN, central 
vascular catheter / peripheral vascular catheter for blood-
stream infection-BSI and urinary catheter for UTI) [13], 
HAI present at admission, date of onset, origin of infec-
tion (if bloodstream infection, source) and microorgan-
isms data.
AM data (including generic or brand name, route, in-
dication, diagnosis/site of infection, reason) were col-
lected when a patient was receiving an AM on the day of 
survey (or in the 24 hours before the day of the survey 
for surgical prophylaxis). Registered drugs were classi-
fied according to the Anatomical Therapeutic Chemical 
(ATC) classification  [14]. AMs included in the survey 
were Anatomical Therapeutic Chemical classes J01 (an-
tibacterials), J02 (antifungals) and J04 (antimycobacte-
rials). Indication for use of systemic AMs was recorded 
according to the following classification: community-
acquired infection, infection acquired in long-term care 
facility (e.g. nursing home) or chronic-care hospital, 
acute hospital acquired infection, surgical prophylax-
is (single dose, one day, more than one day), medical 
prophylaxis, other indications, unknown indication/
reason, unknown/missing information on indication not 
verified during survey  [10]. Data were collected using 
the standard ECDC software HELICSWin.net v. 1.3. 
Statistical analysis was performed using Stata v.13. Dif-
ference in the distribution of nominal variables was as-
sessed using Pearson’s chi-square test with significance 
level set at 0.05. Continuous variables were tested for 
normality of distribution both graphically and by means 
of Shapiro-Wilkinson test, difference in distribution was 
then tested using Kruskal-Wallis test. Prevalence rate 
of HAI was calculated as the percentage of infected pa-
tients over the total number of patients observed during 
each survey. AM use prevalence was calculated as the 
percentage of the number of patients receiving at least 
one AM over the total number of patients observed. Risk 
factors analysis were performed by means of logistic re-
gression in relation to two outcomes: presence of at least 
one HAI and receipt of at least one AM. 
Continuous variables were recoded into categories in 
order to maintain consistency with ECDC PPS  [15] 
and to address the influence of outliers. The final mod-
els for both outcomes were developed by adding those 
risk factors which resulted to be significant (P < 0.2) in 
univariate analysis in a forward stepwise manner  [16]. 
Significance level for inclusion in final model was set 
at p < 0.05. The presence of a central vascular catheter 
or peripheral vascular catheter was excluded from both 
models because of the correlation with the parenteral 
administration of AMs. Presence of relevant invasive de-
vices was considered before the onset of an HAI for the 
HAI regression model. Length of stay in the HAI model 
was considered until the date of HAI onset if an HAI oc-
curred during current hospital stay. Goodness-of-fit was 
assessed on eight smaller random sub-samples of the 
data using the Hosmer–Lemeshow chi square test. The 
discriminatory accuracy of the multiple logistic regres-
sion models was assessed using receiver operating char-
acteristic (ROC) analysis. Standardized prevalence rates 
were calculated by using a 2-step method which takes 
into consideration predicted probabilities of the outcome 
according to the regression model and indirect standard-
ization. The predicted probabilities were used to deter-
mine the mean predicted risk of HAI or AM use for each 
survey. Risk index ratios were calculated by dividing the 
observed (unadjusted) prevalence rates by the mean pre-
dicted risk of each survey, and adjusted prevalence rates 
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were determined by multiplying standardized ratios by 
the observed prevalence rates in the entire study sample.
Results
Overall, 1,239 patients were observed in the three sur-
veys; the mean age was 62.6 years and 47.3% were 
male. Mean length of stay was 9.4 days (median 6 days). 
At the time of survey, a central vascular catheter was 
present in 20.2% of observed patients; a peripheral vas-
cular catheter in 56.0%; a urinary catheter in 35.9% and 
the percentage of mechanically ventilated / intubated pa-
tients was 3.8%. Differences among data collected dur-
ing the three surveys proved to be statistically significant 
(p < 0.05) for: presence of peripheral line, presence of 
central line, McCabe score and surgery since admission. 
The overall prevalence of HAI was 9.6%, with a total 
number of 49 HAIs in 2011, 37 in 2012, and 54 in 2013 
(HAIs to patients ratio: 1.1 in 2011, 1.1 in 2012, 1.3 in 
2013). Case-mix corrected prevalence rates were: 10.1% 
for 2011, 8.9% for 2012 and 9.6% for 2013. UTIs were 
the most common HAI in all three surveys, followed by 
PN (in 2011 and 2012) and bloodstream infections in 
2013 (Tab. I). A total of 82.8% HAIs originated in the 
current hospital. Regression analysis of risk factors asso-
ciated with the onset of at least one HAI shows statistical 
significance for: length of stay at risk 4-7 days (OR: 1.9, 
95%CI 1.1-3.4; p = 0.030), length of stay at risk 8-14 
days (OR: 2.3, 95%CI 1.2-4.3; p = 0.010) and length 
of stay at risk > 3 weeks (OR: 3.8, 95%CI 2.1-7.1; p < 
0.001); McCabe score “Rapidly fatal disease” (OR: 2.4, 
95%CI 1.5-3.8; p < 0.001); use of urinary catheter (OR: 
2.5, 95%CI 1.6-3.7; p < 0.001); mechanical ventilation 
(OR: 2.3, 95%CI 1.1-4.5; p = 0.023). The prevalence of 
HAI was higher in Intensive Care Units in all three sur-
veys. 
At the time of the surveys, results for microbiological 
investigation were available for 120 HAIs (85.0%). 
Escherichia coli was the most common pathogen, 
followed by Klebsiella pneumoniae and Enterococ-
cus faecalis (Tab. II). Escherichia coli was the most 
prevalent pathogen even when stratifying by survey 
and also the most frequent causative pathogen for 
UTI. During the 3-year study period, isolated strains 
of Escherichia coli were frequently third-generation 
cephalosporin resistant (range 10%-20%), but only in 
2011 were they also carbapenem resistant. In 2011, 
33.3% of Klebsiella pneumoniae strains were third-
generation cephalosporin resistant and 16.7% were 
carbapenem resistant. Overall, the AM use preva-
lence was 51.1% (at least one AM). A total of 858 
AMs were administered (Tab. III). Parenteral ad-
ministration was the most prevalent route (69.0% 
in 2011, 74.0% in 2012 and 79.3% in 2013). AMs 
were mainly administered for treatment of an infec-
tion (relative frequency 61.0% in 2011, 56.2% in 
2012 and 70.7% in 2013) and among these mainly for 
treatment of community acquired infections (57.6% 
in 2011, in 2012 59.1%, in 2013 60.1%). Surgical 
prophylaxis was mostly prescribed for more than 
one day (relative frequency: 65.4% in 2011, 72.0% 
in 2012 and 88.9% in 2013). Single dose prophylaxis 
was prescribed in 23.1% in 2011, 20.0% in 2012 and 
11.1% in 2013 (relative frequency). One-day surgi-
cal prophylaxis was the least frequently prescribed. 
Prescription for medical prophylaxis was 19.8% in 
2011, 24.9% in 2012, 15.0% in 2013. Considering all 
three surveys, antibacterials for systemic use (ATC 
group J01) accounted for 93.7% of all prescriptions. 
AMs most frequently administered were: J01MA 
fluoroquinolones (21.7% in 2011, 23.0% in 2012, 
21.8% in 2013), J01CR combinations of penicillins 
including beta-lactamase inhibitors (20.4% in 2011, 
19.2% in 2012, 21.8% in 2013), J01DD third-gen-
eration cephalosporins (22.7% in 2011, 16.6% in 
2012, 16.8% in 2013). Fluoroquinolones were the 
most commonly used AMs in symptomatic lower 
UTI (total 28.8%) and PN (total 24.5%), including 
both community acquired infections and HAI. Risk 
Tab. I. Characters of healthcare associated infections (hAIs).
HAI data Year of survey
2011  
(N = 450a)
2012 
(N = 379)
2013  
(N = 407)
hAI prevalence (at least one hAI) % 10.0 8.7 10.1
Total number of hAIs 49 37 54
Infection Site - No. (%) of hAI by year of survey:
Urinary tract infections 18 (36.7) 9 (24.3) 22 (40.7)
pneumonia 7 (14.3) 9 (24.3) 6 (11.1)
Bloodstream infections (BSI) 5 (10.2) 2 (5.4) 10 (18.5)
Surgical site infections 4 (8.2) 4 (10.8) 3 (5.6)
gastro-intestinal system infections 5 (10.2) 2 (5.4) 2 (3.7)
Other lower respiratory tract infections 2 (4.1) 1 (2.7) 2 (3.7)
Catheter-related infections w/o BSI 2 (5.4)
Other 8 (16.3) 8 (21.6) 9 (16.7)
a 3 missing records excluded
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factors associated with administration of at least one 
AM showing statistical significance in the regression 
model were: patient located in surgical ward (OR: 
1.7, 95%CI 1.1-2.7; p = 0.010) and Intensive Care 
Unit (OR: 2.7, 95%CI 1.2-6.0; p = 0.015); length of 
stay 4-7 days (OR: 1.4, 95%CI 1.1-1.9; p = 0.016); 
length of stay 8-14 days (OR: 1.6, 95%CI 1.1-2.2; p 
= 0.010); patient underwent non-NHSN/minimal sur-
gery during current hospitalization (OR: 1.5, 95%CI 
1.1-2.2; p = 0.013); use of urinary catheter at the time 
of survey (OR: 1.9, 95%CI 1.4-2.4; p < 0.001); me-
chanical ventilation at the time of survey (OR: 2.6, 
95%CI 1.1-6.0; p = 0.030). Case-mix corrected AM 
use prevalence rates were: 54.2% in 2011, 50.5% in 
2012 and 47.9% in 2013.
Discussion
The described prevalence rate of nosocomial infections 
was higher than the values reported in other studies [17-
21] including the ECDC’s 2011 report [15], which esti-
mates a prevalence rate of 6.0% (country range 2.3%–
10.8%) in European acute-care hospitals (6.1% in Italy). 
This difference in the reported values  is due in part to 
the different characteristics of the hospitals included in 
the European survey which collects results from pri-
mary, secondary, tertiary care and specialized hospitals 
in different countries. However, the prevalence rate of 
HAI in FUH remains higher even when comparing re-
sults from tertiary care hospitals only (7.2%). One pos-
sible reason may be the fact that the surveys were carried 
out by independent auditors, to avoid conflicts of interest 
and to ensure the integrity of the auditing process. As con-
Tab. II. Top five microorganisms isolated in healthcare-associated infections and percentage of antimicrobial resistance markers.
Microorganisms No. of isolated microorganisms by year of survey
2011  
(N = 74)
2012  
(N = 28)
2013  
(N = 73)
Escherichia coli 
(%C3G-R) (%Car-R)
24 
(16.7) (16.7)
10 
(20.0) (0.0)
20 
(10.0) (0.0)
Klebsiella pneumoniae 
(%C3G-R) (%Car-R)
6 
(33.3) (16.7)
4 
(0.0) (0.0)
6 
(0.0) (0.0)
Enterococcus faecalis 2 5 5
Candida albicans 5 6
Staphylococcus epidermidis 1 1 6
C3G-R, Third-generation cephalosporin resistance
Car-R, Carbapenem-resistant
Tab. III. Characters of Antimicrobials (AMs).
AM use data Year of survey 
2011 
(N = 450a)
2012 
(N = 379)
2013 
(N = 407)
AM use prevalence (at least one AM) % 54.4 50.1 48.4
Total number of AM 313 265 280
Top ten antimicrobials agents (ATC codes) - No. (%) of AM by 
year of survey:
J01MA Fluoroquinolones 68 (21.7) 61 (23.0) 61 (21.8)
J01CR Combinations of penicillins, incl. beta-lactamase 
inhibitors
64 (20.4) 51 (19.2) 61 (21.8)
J01DD Third-generation cephalosporins 71 (22.7) 44 (16.6) 47 (16.8)
J01GB Aminoglycosides 13 (4.2) 17 (6.4) 17 (6.1)
A07AA Intestinal anti-infectives antibiotics 7 (2.2) 3 (1.1) 2 (0.7)
J01DB First-generation cephalosporins 23 (7.3) 11 (4.2) 6 (2.1)
J01DH Carbapenems 9 (2.9) 11 (4.2) 20 (7.1)
J01XA Glycopeptide antibacterials 11 (3.5) 16 (6.0) 13 (4.6)
J01XD Imidazole derivatives 7 (2.2) 8 (3.0) 13 (4.6)
J02AC Triazole derivatives 9 (2.9) 10 (3.8) 7 (2.5)
J01FA Macrolides 12 (3.8) 9 (3.4) 4 (1.4)
a 3 missing records excluded
ATC, Anatomical Therapeutic Chemical
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what is suggested by the international consensus [30], 
further stressing the need for specific stewardship pro-
grams [31, 32]. Year by year analysis shows a decreas-
ing, although not statistically significant, prevalence of 
AM prescription in FUH, dropping from 54.4% in 2011 
to 48.4% in 2013, a result confirmed by standardization 
through logistic regression model. AM stewardship is a 
critical area of intervention in FUH, aimed at changing 
prescribing practices, leading to a better control of drug 
resistant microorganisms, improved appropriateness of 
antibiotic use and decreased costs.
Conclusions
FUH has a long history of activities aimed at risk 
management and infection control, based on a multi-
modal and multidimensional approach [11]. Moreover, 
the hospital’s infection control policy includes: audit 
and feed-back to improve compliance of the health-
care workforce to good practices; retraining courses 
and educational programs; drafting reminders to sup-
port good practices for workers, patients and caregiv-
ers; continuous surveillance of surgical site infections; 
active support for the WHO Campaign “Save lives: 
clean your hands” since 2006, with the participa-
tion as an international site in the experimentation of 
WHO Guidelines on Hand Hygiene in Health Care 
(Advanced Draft)  [33, 34]. Despite their limitations, 
PPS are not expensive, take little time to carry out and 
need few human resources. PPS are easy repeatable 
and provide meaningful information to use for specific 
targeted interventions. The yearly repetition will be a 
useful means of keeping interest alive on the subject of 
HAI and AM use [35] and highlighting how changes in 
healthcare practices affect outcome variables.
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firmed by existing literature, Intensive Care Units were 
the most affected wards  [15, 17-21]. UTIs were the 
most common HAI in all three surveys in FUH, unlike 
what is reported in other studies where PN and surgi-
cal site infections were more prevalent  [15, 17, 18]. 
Use of urinary catheter, a well known risk factor for 
UTIs [22-24], was higher than what is reported in the 
literature [15, 19, 21]. Prevalence of surgical site infec-
tions was found to be lower than what is reported by 
other similar surveys [15, 17-21]. Appropriate urinary 
catheter indication is certainly an area which requires 
further analysis to assess possible overuse and guide 
practical interventions [25]. Year by year comparison 
of nosocomial infections and risk factors in the three 
surveys delivers substantially constant results even 
when corrected for case-mix by means of logistic re-
gression. Risk factor analysis is consistent with data in 
the literature [15, 19, 21]. Statistically significant risk 
for HAI occurrence is independently associated with 
increased length of stay, McCabe Score “Rapidly fatal 
disease”, use of urinary catheter and mechanical venti-
lation. Mechanical ventilation associated risk suggests 
a need for more effective preventive measures against 
ventilator-associated infections [26]. At the time of the 
surveys, results for microbiological investigation were 
available for 120 HAIs (85.0%). Escherichia coli was 
the most frequent microorganism isolated in all three 
surveys and the most frequent causative pathogen for 
UTI, followed by Klebsiella pneumoniae, Enterococ-
cus faecalis and Candida albicans. These results show 
a higher prevalence of Enterobacteriaceae when com-
pared with the ECDC’s report data [15] which can be 
explained by the higher frequency of UTIs in FUH. 
AM use rates were higher than those reported in the 
literature [15, 19], while the average number of AMs 
to treated patients ratio is consistent with the value re-
ported by ECDC [15], showing no evidence of a higher 
rate of multidrug protocol prescriptions in FUH. Fluo-
roquinolones, third-generation cephalosporins and 
combinations of penicillins (including beta-lactam 
inhibitors) were the most frequent AM prescribed in 
all three surveys, a similar result to other literature 
reports which further underline a widespread use of 
broad spectrum antibiotics combined in multidrug 
protocols that is often necessary to counteract the in-
creasing prevalence of AM resistance [15, 17-19, 27]. 
On the other hand, the excessive and inappropriate 
use of antibiotics is the prime mover of the rapidly 
increasing prevalence of antibiotic-resistant microor-
ganisms [28, 29]. AMs were mainly prescribed to treat 
an infection (mainly community acquired). Medical 
prophylaxis was the second most frequent indication in 
all three surveys. These results are similar to those re-
ported by the ECDC’s 2011 point prevalence survey for 
Italy [15]. Surgical prophylaxis was mostly prescribed 
for more than one day, while one-day surgical prophy-
laxis was the least frequently prescribed. These results 
are substantially similar to those reported by ECDC 
for Italy in 2011 and other similar studies [15, 18, 19], 
underlining that antibiotics are used for longer than 
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